Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Experimental: YB-101
YB-101 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| YB-101 | EXPERIMENTAL | In Part 1, participants will receive YB-101 via subcutaneous injection. Part 2 participants will receive YB-101 via subcutaneous injection. |
| Placebo YB-101 | PLACEBO_COMPARATOR | In Part 1, participants will receive placebo via subcutaneous injection. Part 2 participants will receive placebo via subcutaneous injection. |
| Name | Type | Description |
|---|---|---|
| Experimental: YB-101 | DRUG | YB-101 is administered over a 24 week period. |
| Placebo YB-101 | DRUG | Placebo will be administered over a 24 week period. |
Inclusion Criteria: * Have a documented diagnosis of Graves' Disease confirmed by the presence of thyroid-stimulating hormone receptor antibodies (TRAbs) by medical history or screening laboratory assessment * Have a pre-existing diagnosis of TED or, conversely, no evidence of TED at the ophthalmol...